


Stereochemistry abstracts

Giovanni Desimoni, Giuseppe Faita,\* Alessandro Galbiati,  
Dario Pasini,\* Paolo Quadrelli and Fabio Rancati

*Tetrahedron: Asymmetry* 13 (2002) 333



C<sub>19</sub>H<sub>19</sub>NO<sub>3</sub>  
(4S)-[4-(4-Vinylbenzyloxy)benzyl]-1,3-oxazolidin-2-one


[ $\alpha$ ]<sub>D</sub> = +51.9 (*c* 0.73, CHCl<sub>3</sub>)

Source of chirality: L-tyrosine

Absolute configuration: 4S

Robert Chênevert\* and Dave Caron

*Tetrahedron: Asymmetry* 13 (2002) 339



C<sub>12</sub>H<sub>22</sub>O<sub>6</sub>  
(R)-2-(4-Acetoxyethyl)-4,5-dihydroxypentyl-2-methyl-1,3-dioxolane

E.e. = 90%


[ $\alpha$ ]<sub>D</sub><sup>23</sup> = -2.6 (*c* 2.3, acetone)

Source of chirality: enzymatic desymmetrization

Absolute configuration: R

Robert Chênevert\* and Dave Caron

*Tetrahedron: Asymmetry* 13 (2002) 339



C<sub>12</sub>H<sub>20</sub>O<sub>5</sub>  
(R)-2-(4-Acetoxyethyl)-4,5-epoxypentyl-2-methyl-1,3-dioxolane

E.e. = 90%


[ $\alpha$ ]<sub>D</sub><sup>23</sup> = -6.0 (*c* 1.84, acetone)

Source of chirality: enzymatic desymmetrization

Absolute configuration: R

Jae-Mok Lee, Hyun-Suk Lim and Sung-Kee Chung\*

*Tetrahedron: Asymmetry* 13 (2002) 343




C<sub>18</sub>H<sub>36</sub>ClNO<sub>2</sub>  
(2S,4E)-2-Amino-3-oxo-octadecen-1-ol·HCl


[ $\alpha$ ]<sub>D</sub><sup>25</sup> +24.4 (*c* 0.95, MeOH)

Source of chirality: L-serine


Absolute configuration: 2S (assigned by chemical correlation)

 $C_{18}H_{36}ClNO_2$ (2*R*,4*E*)-2-Amino-3-oxo-octadecen-1-ol·HCl $[\alpha]_D^{25} -25.1$  (*c* 1.28, MeOH)


Source of chirality: D-serine

Absolute configuration: 2*R* (assigned by chemical correlation) $C_{43}H_{63}NO_2Si$ (2*S*,4*E*)-2-[*N*-(Trityl)amino]-1-*O*-*t*-butyldimethylsilyl-3-oxo-4-octadecene $[\alpha]_D^{25} +59.6$  (*c* 1.19, CHCl<sub>3</sub>)

Source of chirality: L-serine

Absolute configuration: 2*S* (assigned by chemical correlation) $C_{43}H_{63}NO_2Si$ (2*R*,4*E*)-2-[*N*-(Trityl)amino]-1-*O*-*t*-butyldimethylsilyl-3-oxo-4-octadecene $[\alpha]_D^{25} -59.8$  (*c* 0.87, CHCl<sub>3</sub>)

Source of chirality: D-serine


Absolute configuration: 2*R* (assigned by chemical correlation) $C_{43}H_{65}NO_2Si$ (2*S*,3*S*,4*E*)-2-[*N*-(Trityl)amino]-1-*O*-*t*-butyldimethylsilyl-4-octadecen-1,3-diol

E.e. &gt;99% (on NMR)

 $[\alpha]_D^{25} -10.9$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: L-serine


Absolute configuration: 2*S*,3*S* (assigned by chemical correlation)

(2*R*,3*R*,4*E*)-2-[*N*-(Trityl)amino]-1-*O*-*t*-butyldimethylsilyl-4-octadecen-1,3-diol

E.e. &gt;99% (on NMR)

 $[\alpha]_D^{25} +10.15$  (*c* 1.25,  $\text{CHCl}_3$ )

Source of chirality: D-serine


Absolute configuration: 2*R*,3*R* (assigned by chemical correlation)

(-)-(S)-1-Phenyl-4-phenylsulfinylbut-1-ene

E.e. 67%, determined by  $^1\text{H}$  NMR with  $\text{Eu}(\text{hfc})_3$  $[\alpha]_D -48$  (*c* 1.0,  $\text{CH}_2\text{Cl}_2$ )

Source of chirality: enantioselective sulfoxidation


Absolute configuration: S (by chemical correlation)



(+)-(R,R)-1-Phenyl-4-phenylsulfanylobutane-1,2-diol

E.e. 76%, determined by  $^1\text{H}$  NMR with  $\text{Eu}(\text{hfc})_3$  $[\alpha]_D +49$  (*c* 0.60,  $\text{CH}_2\text{Cl}_2$ )Source of chirality: asymmetric dihydroxylation with AD-mix  $\beta$ 

Absolute configuration: R (by chemical correlation)




(-)-(S)-4-(Phenylsulfinyl)but-1-ene

E.e. 70%, determined by  $^1\text{H}$  NMR with  $\text{Eu}(\text{hfc})_3$  $[\alpha]_D -131$  (*c* 1.0,  $\text{CH}_2\text{Cl}_2$ )


Source of chirality: enantioselective sulfoxidation

Absolute configuration: S (by chemical correlation)




$C_{11}H_{14}OS$   
(-)-(S)-4-(Tolylsulfinyl)but-1-ene

E.e. 85%, determined by  $^1H$  NMR with Eu(hfc)<sub>3</sub>  
 $[\alpha]_D -118$  (*c* 1.0,  $CH_2Cl_2$ )  
 Source of chirality: enantioselective sulfoxidation  
 Absolute configuration: *S* (by chemical correlation)




$C_{16}H_{18}O_3S$   
(-)-(S,S,S)-1-Phenylsulfinylbutane-1,2-diol

D.e. 100%, >98% e.e. determined by  $^1H$  NMR  
 $[\alpha]_D -125$  (*c* 0.34,  $CH_2Cl_2$ )  
 Source of chirality: enantioselective sulfoxidation and dihydroxylation  
 Absolute configuration: *S,S,S* (by X-ray crystallographic measurement)




$C_{25}H_{23}BrN_2O_5S$   
Phenylmethyl (1*S*)-*N*-[1-[6-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxyethyl]carbamate

E.e. = 80%  
 $[\alpha]_D^{20} = +29$  (*c* 0.59,  $CHCl_3$ )  
 Source of chirality: asymmetric synthesis  
 Absolute configuration: *S*



$C_{25}H_{23}BrN_2O_5S$   
Phenylmethyl (1*S*)-*N*-[2-[6-bromo-1-(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxyethyl]carbamate


E.e. = 24%  
 $[\alpha]_D^{20} = +8$  (*c* 0.53,  $CHCl_3$ )  
 Source of chirality: asymmetric synthesis  
 Absolute configuration: *S*



E.e. = 94%

 $[\alpha]_D^{20} = +47$  (*c* 0.38, CHCl<sub>3</sub>)


Source of chirality: asymmetric synthesis

Absolute configuration: *S*1,1-Dimethylethyl (1*S*)-*N*-[1-[6-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxy]ethylcarbamate

E.e. = 17%

 $[\alpha]_D^{20} = +9$  (*c* 0.30, CHCl<sub>3</sub>)


Source of chirality: asymmetric synthesis

Absolute configuration: *S*1,1-Dimethylethyl (1*S*)-*N*-[2-[6-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxy]ethylcarbamate

E.e. = 86%

 $[\alpha]_D^{20} = +38.6$  (*c* 1.25, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: *S*1,1-Dimethylethyl (1*S*)-*N*-[1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxyethylcarbamate

E.e. = 42%

 $[\alpha]_D^{20} = +11.8$  (*c* 1.20, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: *S*1,1-Dimethylethyl (1*S*)-*N*-[2-[4-methylphenylsulfonyl]-1*H*-indol-3-yl]-2-hydroxyethylcarbamate



E.e. = 75%

 $[\alpha]_D^{20} = +22$  (*c* 0.85, CHCl<sub>3</sub>)


Source of chirality: asymmetric synthesis

Absolute configuration: *S*C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S1,1-Dimethylethyl (1*S*)-*N*-[1-[5-methoxy-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxyethyl]carbamate

E.e. = 3%

 $[\alpha]_D^{20} = +2.5$  (*c* 1.675, CHCl<sub>3</sub>)


Source of chirality: asymmetric synthesis

Absolute configuration: *S*C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S1,1-Dimethylethyl (1*S*)-*N*-[2-[5-methoxy-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxyethyl]carbamate

E.e. = 69%

 $[\alpha]_D^{20} = +7.8$  (*c* 1.90, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: *S*C<sub>22</sub>H<sub>25</sub>BrN<sub>2</sub>O<sub>5</sub>S1,1-Dimethylethyl (1*S*)-*N*-[1-[5-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxyethyl]carbamate

E.e. = 12%


 $[\alpha]_D^{20} = +4.8$  (*c* 1.50, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: *S*C<sub>22</sub>H<sub>25</sub>BrN<sub>2</sub>O<sub>5</sub>S1,1-Dimethylethyl (1*S*)-*N*-[2-[5-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-hydroxyethyl]carbamate


 $[\alpha]_D^{20} = +15$  (*c* 0.32, CHCl<sub>3</sub>)



Source of chirality: asymmetric synthesis

Absolute configuration: *S*1,1-Dimethylethyl (1*S*)-*N*-[1-[6-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-[(4-methylphenyl)sulfonyloxy]ethylcarbamate
 $[\alpha]_D^{20} = +4$  (*c* 1.67, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: *S*1,1-Dimethylethyl (1*S*)-*N*-[1-[6-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-2-azido]ethylcarbamate
 $[\alpha]_D^{20} = +45$  (*c* 0.40, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: *S*(S)-6-Bromo-*N*-[2-azido-1-[(6-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl)ethyl]-<math>\alpha</math>-oxoindole-3-acetamide(S)-3-(6-Bromo-1*H*-indol-3-yl)-6-[6-bromo-1-[(4-methylphenyl)sulfonyl]-1*H*-indol-3-yl]-5,6-dihydro-1*H*-pyrazin-2-one
 $[\alpha]_D^{20} = -27$  (*c* 0.5, acetone)

Source of chirality: asymmetric synthesis


Absolute configuration: *S*




Hamaanthin A

 $[\alpha]_D^{20} = +82$  (*c* 0.135, CH<sub>3</sub>OH)


Source of chirality: asymmetric synthesis

Absolute configuration: *S*(3*S*,6*S*)-3-(6-Bromo-1*H*-indol-3-yl)-6-[6-bromo-1-(toluene-4-sulfonyl)-1*H*-indol-3-yl]-piperazin-2-one $[\alpha]_D^{20} = -35$  (*c* 1.50, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: 3*S*,6*S*(3*R*,6*S*)-3-(6-Bromo-1*H*-indol-3-yl)-6-[6-bromo-1-(toluene-4-sulfonyl)-1*H*-indol-3-yl]-piperazin-2-one $[\alpha]_D^{20} = +16$  (*c* 0.42, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: 3*R*,6*S*(3*S*,6*S*)-3,6-Bis(6-bromo-1*H*-indol-3-yl)piperazin-2-one $[\alpha]_D^{20} = -8$  (*c* 0.17, CH<sub>3</sub>OH)

Source of chirality: asymmetric synthesis


Absolute configuration: 3*S*,6*S*

(3*R*,6*S*)-3,6-Bis(6-bromo-1*H*-indol-3-yl)piperazin-2-one $[\alpha]_D^{20} = -6$  (*c* 0.275, CH<sub>3</sub>OH/acetone = 1:1)


Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*,6*S*1,1-Dimethylethyl (6*S*)-3-[6-bromo-1-(*tert*-butyloxycarbonyl)-1*H*-indol-3-yl]-6-[6-bromo-1-(toluene-4-sulfonyl)-1*H*-indol-3-yl]-5,6-dihydro-2-oxo-1*H*-pyrazine-1-carboxylate $[\alpha]_D^{20} = -70$  (*c* 0.68, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: *S*(6*S*)-3-[6-Bromo-1-(*tert*-butyloxycarbonyl)-1*H*-indol-3-yl]-6-[6-bromo-1-(toluene-4-sulfonyl)-1*H*-indol-3-yl]-5,6-dihydro-1*H*-pyrazin-2-one $[\alpha]_D^{20} = +94$  (*c* 0.64, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: *S*(6*S*)-3-[6-Bromo-1-(*tert*-butyloxycarbonyl)-1*H*-indol-3-yl]-6-[6-bromo-1-(toluene-4-sulfonyl)-1*H*-indol-3-yl]-5,6-dihydro-1-methyl-1*H*-pyrazin-2-one $[\alpha]_D^{20} = -26$  (*c* 0.55, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: *S*




(6S)-3-(6-Bromo-1H-indol-3-yl)-6-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-5,6-dihydro-1-methyl-1H-pyrazin-2-one

 $[\alpha]_D^{20} = -115$  (*c* 0.74, CHCl<sub>3</sub>)


Source of chirality: asymmetric synthesis

Absolute configuration: *S* $C_{28}H_{24}Br_2N_4O_3S$ (3*S*,6*S*)-3-(6-Bromo-1*H*-indol-3-yl)-6-[6-bromo-1-(toluene-4-sulfonyl)-1*H*-indol-3-yl]-1-methylpiperazin-2-one $[\alpha]_D^{20} = -49$  (*c* 0.77, CH<sub>3</sub>Cl)

Source of chirality: asymmetric synthesis


Absolute configuration: 3*S*,6*S* $C_{28}H_{24}Br_2N_4O_3S$ (3*R*,6*S*)-3-(6-Bromo-1*H*-indol-3-yl)-6-[6-bromo-1-(toluene-4-sulfonyl)-1*H*-indol-3-yl]-1-methylpiperazin-2-one $[\alpha]_D^{20} = +12$  (*c* 0.20, CH<sub>3</sub>OH/acetone = 1:1)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*,6*S* $C_{21}H_{18}Br_2N_4O$ (3*S*,6*S*)-3,6-Bis(6-bromo-1*H*-indol-3-yl)-1-methylpiperazin-2-one $[\alpha]_D^{20} = -29$  (*c* 0.37, CH<sub>3</sub>OH/acetone = 1:1)

Source of chirality: asymmetric synthesis


Absolute configuration: 3*S*,6*S*

 $C_{21}H_{18}Br_2N_4O$ 

(3R,6S)-3,6-Bis(6-bromo-1H-indol-3-yl)-1-methylpiperazin-2-one

 $[\alpha]_D^{20} = -32$  (*c* 0.20, CH<sub>3</sub>OH)


Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*,6*S* $C_{21}H_{20}Br_2N_4$ 


Dragmacidin A

 $[\alpha]_D^{20} = +4$  (*c* 0.20, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: 3*R*,6*S* $C_{15}H_{16}O_5$ 3-*O*-Benzoyl-5-deoxy-1,2-*O*-isopropylidene- $\alpha$ -D-*erythro*-pent-4-enofuranose $[\alpha]_D +151.6$  (*c* 1.1, chloroform)

Source of chirality: D-xylose and stereoselective synthesis

Absolute configuration: 1*R*,2*R*,3*R* (assigned by NMR spectroscopy) $C_{15}H_{19}O_4$ 3-*O*-Benzyl-5-deoxy-1,2-*O*-isopropylidene- $\alpha$ -D-*erythro*-pent-4-enofuranose $[\alpha]_D +98.9$  (*c* 1.7, chloroform)

Source of chirality: D-xylose and stereoselective synthesis

Absolute configuration: 1*R*,2*R*,3*R* (assigned by NMR spectroscopy)




$C_{20}H_{21}N_2O_7I$   
3'-(1'S,2'R,3'S)-3'-O-Benzoyl-5'-deoxy-5'-yodo-1,2-O-isopropylidene-4'-oxo-1'-yl-thymine

$[\alpha]_{D05} -93.2$  (*c* 0.93, chloroform)

Source of chirality: D-xylose and stereoselective synthesis

Absolute configuration: 1'S,2'R,3'S (assigned by NMR spectroscopy)




$C_{20}H_{21}N_2O_7I$   
3'-O-Benzoyl-5'-deoxy-5'-yodo-1',2'-O-isopropylidene-alpha-D-ribo-4'-yl-thymine

$[\alpha]_D +26.3$  (*c* 0.92, chloroform)

Source of chirality: D-xylose and stereoselective synthesis

Absolute configuration: 1'R,2'R,3'S,4'R (assigned by NMR spectroscopy)




$C_{20}H_{23}N_2O_6I$   
3'-O-Benzyl-5'-deoxy-5'-yodo-1',2'-O-isopropylidene-alpha-D-ribo-4'-yl-thymine

$[\alpha]_D -30.8$  (*c* 1.1, chloroform)

Source of chirality: D-xylose and stereoselective synthesis

Absolute configuration: 1'R,2'R,3'S,4'R (assigned by NMR spectroscopy)



$C_{34}H_{38}N_2O_{10}I_2$   
1-[3'-O-Benzyl-5'-deoxy-5'-yodo-1',2'-O-isopropylidene-alpha-D-ribo-4'-yl]-3-(1''S,2''R,3''S)-3''-O-benzyl-5''-deoxy-5''-iodo-1'',2''-O-isopropylidene-4''-oxo-1''-yl]uracil


$[\alpha]_D +26.3$  (*c* 0.92, chloroform)

Source of chirality: D-xylose and stereoselective synthesis

Absolute configuration: 1'R,2'R,3'S,4'R,1''S,2''R,3''S (assigned by NMR spectroscopy)

Abdelmajid Selouane, Claude Vaccher, Pierre Villa, Denis Postel  
and Christophe Len\*

*Tetrahedron: Asymmetry* 13 (2002) 407



C<sub>17</sub>H<sub>24</sub>O<sub>5</sub>


(S)-1-O-Pivaloyl-1-(2-(1,3-dioxan-2-yl)phenyl)ethan-1,2-diol

[ $\alpha$ ]<sub>D</sub><sup>22</sup> +35.0 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis using AD-mix  $\alpha$

Abdelmajid Selouane, Claude Vaccher, Pierre Villa, Denis Postel  
and Christophe Len\*

*Tetrahedron: Asymmetry* 13 (2002) 407



C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>


(1*R*,3*S*)-1-(3-Pivaloyloxyethyl)-3-dihydrobenzo[*c*]furan-1-yluracil

[ $\alpha$ ]<sub>D</sub><sup>22</sup> +24.0 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis using AD-mix  $\alpha$

Abdelmajid Selouane, Claude Vaccher, Pierre Villa, Denis Postel  
and Christophe Len\*

*Tetrahedron: Asymmetry* 13 (2002) 407



C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>


(1*S*,3*S*)-1-(3-Pivaloyloxyethyl)-3-dihydrobenzo[*c*]furan-1-yluracil

[ $\alpha$ ]<sub>D</sub><sup>22</sup> -104.2 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis using AD-mix  $\alpha$

Kaoru Nakamura\* and Keishi Takenaka

*Tetrahedron: Asymmetry* 13 (2002) 415



C<sub>6</sub>H<sub>10</sub>O


3-Hexyn-2-ol

E.e. = 98%


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +27.2 (*c* 0.58, Et<sub>2</sub>O)

Source of chirality: lipase-catalyzed resolution


Absolute configuration: *R*

 $C_{18}H_{26}N_2O_6$ D-Xylose-(2*R*,3*R*,4*R*)-5-di-*O*-isopropylidene-[4-(methylphenyl)sulfonyl]hydrazone $[\alpha]_D^{25} = +48$  (*c* 0.6, CHCl<sub>3</sub>)


Source of chirality: D-xylose

Absolute configuration: 2*R*,3*R*,4*R* $C_8H_{14}O_3$ (3*R*)-Hydroxy-(4*R*)-5-isopropylidene-1-pentene $[\alpha]_D^{25} = +6.2$  (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: D-xylose


Absolute configuration: 3*R*,4*R* $C_{13}H_{23}NO_4$ (3*S*)-[(tert-Butoxycarbonyl)amino]-[4*R*]-5-isopropylidene-1-pentene $[\alpha]_D^{25} = -35.3$  (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: D-xylose

Absolute configuration: 3*S*,4*R* $C_9H_{15}NO_4$ (2*S*)-[N-(tert-Butoxycarbonyl)amino]-3-pentenoic acid $[\alpha]_D^{25} = +2.6$  (*c* 1.5, MeOH)

Source of chirality: D-xylose

Absolute configuration: 2*S*




$C_{14}H_{18}O_3$   
1-Phenyl-(3*R*)-hydroxy-(4*R*)-5-isopropylidene-1-pentene

$[\alpha]_D^{25} = +21.2$  (*c* 0.5, CHCl<sub>3</sub>)

Source of chirality: D-xylose

Absolute configuration: 3*R*,4*R*




$C_{15}H_{19}NO_4$   
(2*S*)-[(*tert*-Butoxycarbonyl)amino]-4-phenylbutanoic acid

$[\alpha]_D^{25} = +5.8$  (*c* 1.0, EtOH)

Source of chirality: D-xylose

Absolute configuration: 2*S*




$C_{16}H_{21}NO_4$   
(2*S*)-[N-(*tert*-Butoxycarbonyl)amino]-4-phenylmethyl butanoate

$[\alpha]_D^{25} = -13.1$  (*c* 1.0, MeOH)

Source of chirality: D-xylose

Absolute configuration: 2*S*



$C_{18}H_{31}NOSSe$   
(3*R*,4*S*)-3-(Camphorseleno)-4-(thioacetamido)hexane

E.e. = 100%


$[\alpha]_D^{20} = -97.2$  (*c* 3.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*R*,4*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>18</sub>H<sub>31</sub>NOSSe  
(3*S*,4*R*)-3-(Camphorseleno)-4-(thioacetamido)hexane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>21.6</sup> = +87.9 (*c* 1.5, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*S*,4*R*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>20</sub>H<sub>35</sub>NOSSe  
(4*R*,5*S*)-4-(Camphorseleno)-5-(thioacetamido)octane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>22.7</sup> = -122.1 (*c* 4.65, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*R*,5*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>20</sub>H<sub>35</sub>NOSSe  
(4*S*,5*R*)-4-(Camphorseleno)-5-(thioacetamido)octane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>23</sup> = +113.2 (*c* 4.05, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*S*,5*R*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>22</sub>H<sub>39</sub>NOSSe  
(4*R*,5*S*)-4-(Camphorseleno)-5-(thiobutyramido)octane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>20.2</sup> = -109.9 (*c* 1.1, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*R*,5*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>22</sub>H<sub>39</sub>NOSSe  
(4S,5R)-4-(Camphorseleno)-5-(thiobutyramido)octane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>24.4</sup> = -51.4 (*c* 0.59, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*S*,5*R*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>17</sub>H<sub>27</sub>NOSSe  
(4*R*,5*S*)-4-(Camphorseleno)-5-(thiobenzamido)octane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>20.3</sup> = +82.0 (*c* 1.4, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*R*,5*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>17</sub>H<sub>27</sub>NOSSe  
(3*S*,4*R*)-3-(Camphorseleno)-4-(thiobenzamido)octane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>24.9</sup> = +3.0 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 3*S*,4*R*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>22</sub>H<sub>39</sub>NOSSe  
(5*R*,6*S*)-5-(Camphorseleno)-6-(thioacetamido)decane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>21.3</sup> = -46.6 (*c* 5.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 5*R*,6*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>22</sub>H<sub>39</sub>NOSSe  
(5S,6R)-5-(Camphorseleno)-6-(thioacetamido)decane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>22.9</sup> = +66.2 (*c* 4.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 5*S*,6*R*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>20</sub>H<sub>26</sub>NOSSe  
(2*S*)-1-(Camphorseleno)-2-(thioacetamido)-2-phenylethane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>22.6</sup> = -39.0 (*c* 2.7, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>20</sub>H<sub>26</sub>NOSSe  
(2*R*)-1-(Camphorseleno)-2-(thioacetamido)-2-phenylethane

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>21.8</sup> = +30.6 (*c* 2.1, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>8</sub>H<sub>15</sub>NS  
(4*S*,5*S*)-4,5-Diethyl-2-methyl-4,5-dihydro-1,3-thiazole

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>15.4</sup> = -76.4 (*c* 0.4, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*S*,5*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>10</sub>H<sub>19</sub>NS  
(4S,5S)-2-Methyl-4,5-dipropyl-4,5-dihydro-1,3-thiazole

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>24</sup> = -258.0 (*c* 0.9, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*S*,5*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>12</sub>H<sub>23</sub>NS  
(4*R*,5*R*)-2,4,5-Tripropyl-4,5-dihydro-1,3-thiazole

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>20.0</sup> = +59.2 (*c* 0.5, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*R*,5*R*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>15</sub>H<sub>21</sub>NS  
(4*S*,5*S*)-2-Phenyl-4,5-dipropyl-4,5-dihydro-1,3-thiazole

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>24.7</sup> = -127.0 (*c* 0.35, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*S*,5*S*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>12</sub>H<sub>23</sub>NS  
(4*R*,5*R*)-4,5-Dibutyl-2-methyl-4,5-dihydro-1,3-thiazole

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>16.3</sup> = +62.7 (*c* 2.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*R*,5*R*

Marcello Tiecco,\* Lorenzo Testaferri, Claudio Santi,  
Cristina Tomassini, Francesca Marini, Luana Bagnoli and  
Andrea Temperini

*Tetrahedron: Asymmetry* 13 (2002) 429



C<sub>10</sub>H<sub>11</sub>NS

(4*S*)-2-Methyl-4-phenyl-4,5-dihydro-1,3-thiazole

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>21.3</sup> = -21.2 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: 4*S*

Félix Busqué, Pedro de March,\* Marta Figueredo, Josep Font,\*  
Timothy Gallagher and Sergio Milán

*Tetrahedron: Asymmetry* 13 (2002) 437



C<sub>11</sub>H<sub>19</sub>NO<sub>2</sub>S

(*S*)-3,4-Dihydro-5-methylthio-2-pivaloyloxymethyl-2*H*-pyrrole

E.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +22.6 (*c* 10.6, CHCl<sub>3</sub>)

Source of chirality: ethyl (*S*)-pyroglutamate

Absolute configuration: *S*

Félix Busqué, Pedro de March,\* Marta Figueredo, Josep Font,\*  
Timothy Gallagher and Sergio Milán

*Tetrahedron: Asymmetry* 13 (2002) 437



C<sub>10</sub>H<sub>17</sub>NO<sub>2</sub>

(*S*)-3,4-Dihydro-2-pivaloyloxymethyl-2*H*-pyrrole

E.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +64.4 (*c* 6.7, CHCl<sub>3</sub>)

Source of chirality: ethyl (*S*)-pyroglutamate

Absolute configuration: *S*

Félix Busqué, Pedro de March,\* Marta Figueredo, Josep Font,\*  
Timothy Gallagher and Sergio Milán

*Tetrahedron: Asymmetry* 13 (2002) 437



C<sub>16</sub>H<sub>23</sub>NO<sub>7</sub>


Dimethyl (3a*S*,6*S*)-3a,4,5,6-tetrahydro-6-pivaloyloxymethylpyrrolo[1,2-*b*]isoxazole-2,3-dicarboxylate

E.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -167.5 (*c* 7.5, CHCl<sub>3</sub>)

Source of chirality: ethyl (*S*)-pyroglutamate

Absolute configuration: 3a*S*,6*S*



C<sub>8</sub>H<sub>13</sub>NO<sub>2</sub>S


Ethyl (S)-3,4-dihydro-5-methylthio-2*H*-pyrrole-2-carboxylate

E.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +80.6 (*c* 6.0, CHCl<sub>3</sub>)

Source of chirality: ethyl (S)-pyroglutamate

Absolute configuration: *S*



C<sub>7</sub>H<sub>11</sub>NO<sub>2</sub>


Ethyl (S)-3,4-dihydro-2*H*-pyrrole-2-carboxylate

E.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +14.1 (*c* 8.5, CHCl<sub>3</sub>)

Source of chirality: ethyl (S)-pyroglutamate

Absolute configuration: *S*



C<sub>5</sub>H<sub>9</sub>NOS


(*S*)-4,5-Dihydro-5-hydroxymethylpyrrole-2(3*H*)-thione

E.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +13.4 (*c* 1.9, CHCl<sub>3</sub>)

Source of chirality: ethyl (S)-pyroglutamate

Absolute configuration: *S*



C<sub>10</sub>H<sub>17</sub>NO<sub>3</sub>

(*S*)-4,5-Dihydro-5-pivaloyloxymethyl-2(3*H*)-pyrrolone

E.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +32.0 (*c* 5.2, CHCl<sub>3</sub>)

Source of chirality: ethyl (S)-pyroglutamate


Absolute configuration: *S*

E.e. = 100%

$[\alpha]_D^{20} = -40.5$  (*c* 5.1, CHCl<sub>3</sub>)

Source of chirality: ethyl (*S*)-pyroglutamate

Absolute configuration: *S*



C<sub>15</sub>H<sub>25</sub>NO<sub>5</sub>

(*S*)-*N*-(*tert*-Butoxycarbonyl)-4,5-dihydro-5-pivaloyloxymethyl-2(3*H*)-pyrrolone